Fig 1: Splicing of candidate Mcl1 regulators and impact of knockdown on Mcl1 protein stability. (a) RT-PCR with primers recognizing major splice isoforms for the indicated genes (see Materials and Methods) demonstrates an increase in alternate donor site usage in BCLX, generating the pro-apoptotic BCLX-S, and in exon skipping in BAX, GSK3B, HUWE1 and BTRC with knockdown of spliceosome components SART1, UBL5 (minor) and/or PRPF8; (b) Mcl1 protein stability was assessed following siRNA knockdown of UBL5, PRPF8 and PSMD14. Cells were harvested after treatment for the indicated period with cyclohexamide to inhibit protein synthesis and blotted for Mcl1 and tubulin. siSham=non-targeting (control) siRNA; FB, fetal brain
Fig 2: Effects of knockdown of identified hits on Mcl1 mRNA and protein. (a and b) IMR5 and NLF cells were transfected with siRNAs to the indicated genes for 72 h, and protein and mRNA were harvested. PSMD14 knockdown leads to increased Mcl1 protein (relative to β-tubulin loading control) and mRNA, while knockdown of the spliceosome components PRPF8, UBL5 or SART1 leads to (a) reduced Mcl1 protein but with (b) increased MCL1-L mRNA for most, rather than reduced mRNA. (c and d) Complementary QPCR and RT-PCT methods concordantly demonstrate increased splicing toward MCL1-S following knockdown of spliceosome complex members PRPF8, UBL5 or SART1 leading to an increased MCL1-S/MCL1-L ratio. siSham, non-targeting (control) siRNA; error bars, S.E.M. ND, not determined as siMcl1 led to loss of all viable cells. *, P-values ≤0.05 versus siSham. Data are representative of at least two independent experiments
Fig 3: Depletion of PRPF8 causes a decrease in BRCA1 foci, whereas PlaB treatment causes a decrease in both BRCA1 and 53BP1 fociCells were transfected with the siRNAs shown and cultured for 3 days prior to IR treatment (10 Gy) and 6 hr recovery. For small molecule treatments, cells were transfected with siCTRL for consistency, pre-treated with PlaB, DRB, or vehicle (DMSO) (2hrs), IR treatment (10 Gy) and 6 hr recovery in the presence of the small molecules or vehicle. Notably, the total treatment timing for these experiments is the same as experiments in Figure2 Shown are representative images of BRCA1, 53BP1, and γH2AX staining, for such treatments (scale bar = 10 μm). Shown is the percentage cells showing ≥10 foci for each marker shown distinct from siCTRL: *P ≤ 0.0042, †P = 0.034. N = 3, 50 cells analyzed per experiment.
Fig 4: Malignant ascitic fluids after chemotherapy are enriched with spliceosomal components.A Experimental scheme for proteomic analysis of the ascites samples. B Hierarchical clustering dendrogram of proteomic profiles of paired ascitic fluids before (red) and after (blue) chemotherapy. C Left panel: Venn diagram representing the proteins identified in ovarian cancer ascitic fluids before chemotherapy (blue circle), ovarian cancer ascitic fluids after chemotherapy (red circle), and cirrhosis ascitic fluids (yellow circle, according to our previously published data). Right panel: Results of the KEGG enrichment analysis of proteins identified only in ovarian cancer ascites after chemotherapy (p-values are indicated). D RT-qPCR analysis of 9 spliceosomal snRNAs in paired ascitic fluids before and after chemotherapy. Bars represent the level of each snRNA in ascitic fluid after therapy compared to samples before therapy (n = 3 biologically independent samples). Data represent the mean values ± SD (standard deviation). E RT-qPCR analysis of spliceosomal snRNAs in pool of ascitic fluids from 3 patients after immunodepletion of snRNP complexes (using a mix of antibodies against U2AF1, SF3B1, and PRPF8) or extracellular vesicles (using an antibody against CD63) (n = 3 biologically independent samples). Data represent the mean values ± SD. F Nanoparticle tracking analysis of extracellular vesicles isolated from paired ovarian cancer ascitic fluids or secretomes (secretomes were collected as indicated in Fig. 3B) before (blue) and after (red) chemotherapy (n = 14 biologically independent samples). Data represent the mean values ± SD. The p-value was obtained by two-tailed unpaired Student’s t test (D, E, F). Source data are provided as a Source Data file.
Fig 5: U5 core components are required for MRV modulation of cellular AS and are reduced during infection by μ2. (A) Validation of the KD efficiency for EFTUD2, PRPF8 and SNRNP200 by western blot in mock- and T3DS-infected L929 cells. (B) Difference in splicing (ΔPSI) between infected and mock L929 cells in control siRNA or EFTUD2, PRPF8, and SNRNP200 siRNA-treated cells. Respective standard deviation for the mock and infected cells were added when calculating the standard deviation for the ΔPSI. n = 3, biological replicates, unpaired two-tailed Student's t-test (ns, P > 0.05; *P ≤ 0.05; **P ≤ 0.01) comparing each condition against the control siRNA. (C) Protein levels of U5 snRNP components EFTUD2, PRPF8 and SNRNP200 in mock, T3DS and T3DK infected L929 cells. The membranes were H2O2-inactived and probed again against actin (EFTUD2, U2AF35) or vinculin (PRPF8, SNRNP200) as a loading control; a representative loading control is shown. On the right, the cumulative results for three western blots are summarized in a bar graph. The U2 snRNP protein U2AF35 was probed as a control. n = 3, biological replicates, unpaired two-tailed Student's t-test (ns, P > 0.05; *P ≤ 0.05; **P ≤ 0.01) comparing infected cells against control cells. (D) Impact of the ectopic expression of μ2 on U5 components protein levels at 24h and 48h in 293T cells. The U2 snRNP protein U2AF35 was probed as a control. The membranes were H2O2-inactived and probed again against actin (EFTUD2, U2AF35) or vinculin (PRPF8, SNRNP200) as a loading control; a representative loading control is shown. (E) Splicing profiles (PSI) of the HNRNPA2B1, TBP, and the negative control SERBP1 AS minigene reporters upon expression of the different μ2 constructs at 48 h. PCR amplicons were resolved using capillary electrophoresis and quantified using relative fluorescence. n = 3, biological replicates, unpaired two-tailed Student's t-test (ns, P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001) against the GFP alone condition.
Supplier Page from Abcam for Anti-PRPF8/Prp8 antibody